The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

被引:45
|
作者
Davis, MP [1 ]
Homsi, J [1 ]
机构
[1] Cleveland Clin Fdn, Harry R Horvitz Ctr Palliat Med, Cleveland, OH 44195 USA
关键词
CYP2D6; palliative medicine; drug metabolism; drug interactions; ethnic differences; pharmacokinetics;
D O I
10.1007/s005200000222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The enzymes in the cytochrome p450 monooxygenase system (CYP) are the major enzymes responsible for metabolizing medications. The CYP2D6 isomer is responsible for metabolizing certain opioids, neuroleptics, antidepressants and cardiac medications. Owing to CYP2D6's low capacity and high affinity it is easily saturated by substrate and/or inhibited, resulting in pharmacokinetic interactions. Polymorphisms of the structural gene are common, leading to wide inter-individual and ethnic differences in drug metabolism. Clinically important drug interactions, which may be anticipated in the palliative medicine population, are reviewed.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 50 条
  • [31] Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin
    Haritos, VS
    Ghabrial, H
    Ahokas, JT
    Ching, MS
    PHARMACOGENETICS, 2000, 10 (07): : 591 - 603
  • [32] The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
    Chen, SQ
    Chou, WH
    Blouin, RA
    Mao, ZP
    Humphries, LL
    Meek, C
    Neill, JR
    Martin, WL
    Hays, LR
    Wedlund, PJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) : 522 - 534
  • [34] Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population
    Salyakina, Daria
    Roy, Sharmeen
    Wang, Weize
    Oliva, Mailin
    Akhouri, Rohan
    Sotto, Ileana
    Mulas, Nicole
    Solano, Rafaela
    Fernandez, Jose R.
    Sanchez, Stephanie
    Shamshad, Uzma
    Perlyn, Chad
    McCafferty-Fernandez, Jennifer
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (09):
  • [35] Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects
    Gaedigk, A
    Ndjountché, L
    Gaedigk, R
    Leeder, JS
    Bradford, LD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) : 575 - 576
  • [36] Persistent mood disorders and cytochrome P450 2D6:: influence of the CYP2D6 gene duplication on the development of persistence
    Kawanishi, C
    Ågren, H
    Bertilsson, L
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (03) : 180 - 180
  • [37] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    Ingelman-Sundberg, M
    PHARMACOGENOMICS JOURNAL, 2005, 5 (01): : 6 - 13
  • [38] Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    M Ingelman-Sundberg
    The Pharmacogenomics Journal, 2005, 5 : 6 - 13
  • [39] Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor Binding
    Wang, An
    Stout, C. David
    Zhang, Qinghai
    Johnson, Eric F.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (08) : 5092 - 5104
  • [40] Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity
    Magliocco, Gaelle
    Desmeules, Jules
    Matthey, Alain
    Quiros-Guerrero, Luis M.
    Bararpour, Nasim
    Joye, Timothee
    Marcourt, Laurence
    Queiroz, Emerson F.
    Wolfender, Jean-Luc
    Gloor, Yvonne
    Thomas, Aurelien
    Daali, Youssef
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (23) : 4708 - 4725